https://doi.org/10.4081/btvb.2023.81
Is non-alcoholic fatty liver disease a prothrombotic risk factor?
Submitted: 16 April 2023
Accepted: 28 April 2023
Published: 19 May 2023
Accepted: 28 April 2023
Abstract Views: 473
PDF: 158
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Not available
Ajmera V, Cepin S, Tesfai K, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2022; Available from: https://www.sciencedirect.com/science/article/pii/S0168827822033025
DOI: https://doi.org/10.1016/j.jhep.2022.11.010
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Amp Hepatol. 2013; 10:330–45.
DOI: https://doi.org/10.1038/nrgastro.2013.41
Stine JG, Argo CK, Pelletier SJ, et al. Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis. World J Hepatol. 2017; 9:139–46.
DOI: https://doi.org/10.4254/wjh.v9.i3.139
Tripodi A, Fracanzani AL, Primignani M, et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014; 61:148–54.
DOI: https://doi.org/10.1016/j.jhep.2014.03.013
Tripodi A. Detection of procoagulant imbalance. Modified endogenous thrombin potential with results expressed as ratio of values with-to-without thrombomodulin. Thromb Haemost. 2017; 117:830–6.
DOI: https://doi.org/10.1160/TH16-10-0806
Potze W, Siddiqui MS, Boyett SL, Adelmeijer J, et al. Preserved hemostatic status in patients with non-alcoholic fatty liver disease. J Hepatol. 2016; 65: 980–7.
DOI: https://doi.org/10.1016/j.jhep.2016.06.001
Cerletti C, Colucci M, Storto M, Semeraro F, et al. Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. Br J Nutr. 2020; 123:190–7.
DOI: https://doi.org/10.1017/S0007114519002484
Valenti L, Tripodi A, La Mura V, et al. Clinical and genetic determinants of the fatty liver-coagulation balance interplay in individuals with metabolic dysfunction. JHEP Rep. 2022; 4:100598.
DOI: https://doi.org/10.1016/j.jhepr.2022.100598
Paolini E, Longo M, Corsini A, Dongiovanni P. The Non-Invasive Assessment of Circulating D-Loop and mt-ccf Levels Opens an Intriguing Spyhole into Novel Approaches for the Tricky Diagnosis of NASH. Int J Mol Sci. 2023; 24:23-31.
DOI: https://doi.org/10.3390/ijms24032331
Pasarín M, La Mura V, Gracia-Sancho J, et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PloS One. 2012; 7:e32785.
DOI: https://doi.org/10.1371/journal.pone.0032785
Tripodi A, Lombardi R, Primignani M, et al. Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. Biomedicines. 2022; 10:249.
DOI: https://doi.org/10.3390/biomedicines10020249
Kopec AK, Joshi N, Towery KL, et al. Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. J Pharmacol Exp Ther. 2014; 351:288–97.
DOI: https://doi.org/10.1124/jpet.114.218545
How to Cite
Bitto, N., La Mura, V., Fracanzani, A. L., & Tripodi, A. (2023). Is non-alcoholic fatty liver disease a prothrombotic risk factor?. Bleeding, Thrombosis and Vascular Biology, 2(2). https://doi.org/10.4081/btvb.2023.81
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Alessandro Pezzini, The balance between hemorrhage and thrombosis in patients surviving spontaneous intracerebral bleeding: the nightmare of a neurologist , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Guest Editors: Anna Falanga, Benjamin Brenner, Alok A. Khorana, Welcome to the 12th ICTHIC! , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024): 12th ICTHIC
- Tiziano Barbui, Clonal hematopoiesis and inflammation: a link with thrombosis and malignancy , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Rossella Marcucci, Rosanna Abbate, What is the gender of thrombosis? A natural model of precision medicine , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Daniela Poli, Emilia Antonucci, Gualtiero Palareti, Roberto Facchinetti, Pietro Falco, Giuseppina Serricchio, Teresa Lerede, Lucilla Masciocco, Paolo Gresele, Sophie Testa, Major bleedings in mechanical prosthetic heart valves patients on Vitamin K antagonist treatment. Data from the PLECTRUM Study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Anna Falanga, Hugo Ten Cate, Bianca Rocca, How to manage antithrombotic treatments in thrombocytopenic patients with cancer. Comments on the European Haematology Association guidelines , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Luca D'Ambrosio, Maurizio Forte, Giacomo Frati, Sebastiano Sciarretta, Role of platelet autophagy in cardiovascular diseases , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Giovanni de Gaetano, Well begun is half done , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Società Italiana per lo Studio dell'Emostasi e Trombosi – SISET, 28th SISET National Congress | Rome, 6-9 November 2024 , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
- Gary E. Raskob, Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024): 12th ICTHIC
You may also start an advanced similarity search for this article.
